203 related articles for article (PubMed ID: 32216043)
1. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
Jobczyk M; Stawiski K; Fendler W; Różański W
Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
[TBL] [Abstract][Full Text] [Related]
2. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
[TBL] [Abstract][Full Text] [Related]
3. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
Ravvaz K; Walz ME; Weissert JA; Downs TM
J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
[TBL] [Abstract][Full Text] [Related]
4. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
Jobczyk M; Stawiski K; Kaszkowiak M; Rajwa P; Różański W; Soria F; Shariat SF; Fendler W
Eur Urol Oncol; 2022 Feb; 5(1):109-112. PubMed ID: 34092528
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of EORTC And CUETO Risk Tables in Terms of the Prediction of Recurrence and Progression in All Non-Muscle-Invasive Bladder Cancer Patients.
Dalkilic A; Bayar G; Kilinc MF
Urol J; 2019 Feb; 16(1):37-43. PubMed ID: 30120763
[TBL] [Abstract][Full Text] [Related]
6. Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.
Lammers RJ; Palou J; Witjes WP; Janzing-Pastors MH; Caris CT; Witjes JA
BJU Int; 2014 Aug; 114(2):193-201. PubMed ID: 24304638
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
Krajewski W; Aumatell J; Subiela JD; Nowak Ł; Tukiendorf A; Moschini M; Basile G; Poletajew S; Małkiewicz B; Del Giudice F; Maggi M; Chung BI; Cimadamore A; Galosi AB; Fave RFD; D'Andrea D; Shariat SF; Hornak J; Babjuk M; Chorbińska J; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Panunzio A; Alvarez-Maestro M; Simone G; Mastroianni R; Łaszkiewicz J; Lonati C; Zamboni S; Simeone C; Niedziela Ł; Candela L; Macek P; Contieri R; Hidalgo BG; Rivas JG; Sosnowski R; Mori K; Mir C; Soria F; González-Padilla DA; Faba ÒR; Palou J; Ploussard G; Rajwa P; Hałoń A; Laukhtina E; Pradere B; Tully K; Burgos FJ; Cidre MÁJ; Szydełko T;
Urol Oncol; 2022 Nov; 40(11):491.e11-491.e19. PubMed ID: 35851185
[TBL] [Abstract][Full Text] [Related]
8. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
Zhang G; Steinbach D; Grimm MO; Horstmann M
World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
[TBL] [Abstract][Full Text] [Related]
9. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.
Xylinas E; Kent M; Kluth L; Pycha A; Comploj E; Svatek RS; Lotan Y; Trinh QD; Karakiewicz PI; Holmang S; Scherr DS; Zerbib M; Vickers AJ; Shariat SF
Br J Cancer; 2013 Sep; 109(6):1460-6. PubMed ID: 23982601
[TBL] [Abstract][Full Text] [Related]
11. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
12. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
13. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
14. Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models.
Choi SY; Ryu JH; Chang IH; Kim TH; Myung SC; Moon YT; Kim KD; Kim JW
Korean J Urol; 2014 Oct; 55(10):643-9. PubMed ID: 25324946
[TBL] [Abstract][Full Text] [Related]
15. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
16. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
17. Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder.
Krajewski W; Rodríguez-Faba O; Breda A; Pisano F; Poletajew S; Tukiendorf A; Zdrojowy R; Kołodziej A; Palou J
Actas Urol Esp (Engl Ed); 2019 Oct; 43(8):445-451. PubMed ID: 31155372
[TBL] [Abstract][Full Text] [Related]
18. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
19. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models.
Xu T; Zhu Z; Zhang X; Wang X; Zhong S; Zhang M; Shen Z
Urology; 2013 Aug; 82(2):387-93. PubMed ID: 23759377
[TBL] [Abstract][Full Text] [Related]
20. Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups.
Piao XM; Kim SK; Byun YJ; Zheng CM; Kang HW; Kim WT; Kim YJ; Lee SC; Kim WJ; Moon SK; Choi YH; Yun SJ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]